As cost-sharing increasingly shifts toward employees, employers are facing growing scrutiny over their pharmacy benefit strategies. Employees, frustrated by rising […]
By Beckie Fenrick, PharmD, MBA; Emily Crisano, PharmD, RPh; and Jason Peterson, RPh The first quarter of 2025 has brought
By Beckie Fenrick, PharmD, MBA; Emily Crisano, PharmD, RPh; and Jason Peterson, RPh The market for GLP-1 receptor agonists is
By Bethany Hruschak, Senior Manager, Pricing and Analytics Managing pharmacy costs is an essential but complex task for organizations striving
Navion conducted an independent rebate and discount reconciliation for a 3,400-life group, uncovering $660,000 in rebates and discounts value initially missed by the PBM’s own reconciliation process.
By Beckie Fenrick, PharmD, MBA Navigating the evolving rebate landscape requires in-depth expertise, especially as regulatory changes and PBM strategies
The biosimilar landscape is continuing to rapidly evolve, and 2025 marks a pivotal year for payers seeking cost-saving opportunities. With Stelara biosimilars making their debut and Humira biosimilars continuing to gain traction, plan sponsors will have more options than ever to control costs while ensuring members have access to the essential therapies they need.
Already a Navion Partner?
Access co-branded resources and strategy tools via our Partner Portal.
Join our Newsletter
Stay up to date on features and releases.
